NO20000736L - FremgangsmÕte ved bestemmelse av transformerende effekt hos et transformerende middel - Google Patents

FremgangsmÕte ved bestemmelse av transformerende effekt hos et transformerende middel

Info

Publication number
NO20000736L
NO20000736L NO20000736A NO20000736A NO20000736L NO 20000736 L NO20000736 L NO 20000736L NO 20000736 A NO20000736 A NO 20000736A NO 20000736 A NO20000736 A NO 20000736A NO 20000736 L NO20000736 L NO 20000736L
Authority
NO
Norway
Prior art keywords
apoptin
cells
cancer
normal
agents
Prior art date
Application number
NO20000736A
Other languages
English (en)
Other versions
NO326659B1 (no
NO20000736D0 (no
Inventor
Mathieu Hubertus Mari Noteborn
Original Assignee
Leadd Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leadd Bv filed Critical Leadd Bv
Publication of NO20000736D0 publication Critical patent/NO20000736D0/no
Publication of NO20000736L publication Critical patent/NO20000736L/no
Publication of NO326659B1 publication Critical patent/NO326659B1/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
  • Measurement Of Current Or Voltage (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
NO20000736A 1997-08-12 2000-02-14 Fremgangsmate ved bestemmelse av transformerende effekt hos et mulig transformerende middel ved bestemmelse av apoptoseinduserende aktivitet NO326659B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97202501 1997-08-12
PCT/NL1998/000457 WO1999008108A1 (en) 1997-08-12 1998-08-11 Determining the transforming capability of agents

Publications (3)

Publication Number Publication Date
NO20000736D0 NO20000736D0 (no) 2000-02-14
NO20000736L true NO20000736L (no) 2000-04-11
NO326659B1 NO326659B1 (no) 2009-01-26

Family

ID=8228640

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000736A NO326659B1 (no) 1997-08-12 2000-02-14 Fremgangsmate ved bestemmelse av transformerende effekt hos et mulig transformerende middel ved bestemmelse av apoptoseinduserende aktivitet

Country Status (16)

Country Link
US (1) US6528247B1 (no)
EP (1) EP1004021B1 (no)
JP (1) JP4287588B2 (no)
KR (1) KR20010022812A (no)
AT (1) ATE283478T1 (no)
AU (1) AU756587B2 (no)
BR (1) BR9811163A (no)
CA (1) CA2301401C (no)
CZ (1) CZ299874B6 (no)
DE (1) DE69827805T2 (no)
NO (1) NO326659B1 (no)
NZ (1) NZ502800A (no)
PL (1) PL196605B1 (no)
RU (1) RU2214598C2 (no)
SK (1) SK286235B6 (no)
WO (1) WO1999008108A1 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW514581B (en) * 1999-09-02 2002-12-21 Ciba Sc Holding Ag A method of protecting wood against light-induced degradation by treatment with an impregnation which penetrates the surface of the wood
EA005933B1 (ru) * 1999-09-02 2005-08-25 Леадд Б.В. Апоптин-ассоциированный белок
WO2001042461A2 (en) 1999-12-10 2001-06-14 Leadd B.V. Apoptin-associating protein
EP1199363A1 (en) 2000-10-20 2002-04-24 Leadd B.V. Phosphorylation modifications of apoptin
PT1377667E (pt) * 2001-03-30 2009-03-13 Leadd Bv Proteínas de fusão para o tratamento específico de cancro e doenças auto-imunitárias
SE0302312D0 (sv) * 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
AU2003904086A0 (en) 2003-08-04 2003-08-21 Cochlear Limited Implant battery short circuit protection
DK2658872T3 (da) 2010-12-27 2020-10-12 Apo T B V Polypeptid, der binder aberrerende celler og inducerer apoptose
WO2013048243A1 (en) 2011-09-29 2013-04-04 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
JP2015504895A (ja) 2012-01-13 2015-02-16 エーピーオー‐ティー ビー．ヴイ． 毒性部分を備える異常細胞拘束性免疫グロブリン

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9002008A (nl) 1990-09-12 1992-04-01 Stichting Centr Diergeneeskund Recombinant dna en rna en daarvan afgeleide produkten.
KR0162670B1 (ko) * 1991-01-15 1999-05-01 마르쿠 잘카넨 세포의 악성 전형을 나타내기 위한 조직 및 체액과 같은 생물학적 물질에서의 신데칸 내용물의 검출
EP0878546A1 (en) 1997-04-15 1998-11-18 Leadd B.V. A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or apoptin
CZ82692A3 (en) * 1992-03-19 1994-02-16 Prirodovedecka Fakulta Uk Method of testing cyctotoxicity and genotoxicity of chemicals
ATE241808T1 (de) 1995-06-07 2003-06-15 Leadd Bv Verwendungen von apoptin
JPH1015250A (ja) 1996-06-28 1998-01-20 Sega Enterp Ltd ゲーム装置
EP0921192A1 (en) * 1997-12-03 1999-06-09 Leadd B.V. Molecules interacting with apoptin
EP0927757A1 (en) * 1997-12-03 1999-07-07 Leadd B.V. Methods and means for inducing apoptosis by interfering with Bip-like proteins

Also Published As

Publication number Publication date
JP2001512829A (ja) 2001-08-28
CZ299874B6 (cs) 2008-12-17
ATE283478T1 (de) 2004-12-15
DE69827805D1 (de) 2004-12-30
SK286235B6 (sk) 2008-06-06
NZ502800A (en) 2002-10-25
US6528247B1 (en) 2003-03-04
DE69827805T2 (de) 2005-12-15
PL338683A1 (en) 2000-11-20
WO1999008108A1 (en) 1999-02-18
AU8752998A (en) 1999-03-01
SK1902000A3 (en) 2000-11-07
EP1004021B1 (en) 2004-11-24
AU756587B2 (en) 2003-01-16
JP4287588B2 (ja) 2009-07-01
CZ2000479A3 (cs) 2000-06-14
BR9811163A (pt) 2000-07-25
RU2214598C2 (ru) 2003-10-20
NO326659B1 (no) 2009-01-26
KR20010022812A (ko) 2001-03-26
EP1004021A1 (en) 2000-05-31
CA2301401C (en) 2008-10-21
CA2301401A1 (en) 1999-02-18
PL196605B1 (pl) 2008-01-31
NO20000736D0 (no) 2000-02-14

Similar Documents

Publication Publication Date Title
NO20000736L (no) FremgangsmÕte ved bestemmelse av transformerende effekt hos et transformerende middel
DE69933989D1 (de) Biomarker und targets für die diagnose, prognose und behandlung von prostat krankheiten
NZ502527A (en) Catalytic monoclonal antibodies raised to proteins in aggregated form, and use to treat alzheimers, atherosclerosis, amyloidosis and prions disease
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
IS4379A (is) Seyði úr hákarlabrjóski með virkni gegn æðamyndunog æxlisbælandi áhrif; aðferð við framleiðslu þess
ATE226643T1 (de) Genetische diagnose und pharmazeutische produkte zur behandlung von prostatakrebs
TR199902803T2 (xx) VCAM-1' in te�hisinin daralt�lmas� i�in bile�ikler ve metodlar.
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE275411T1 (de) Verwendung von phyllanthus zur behandlung von chronisch entzündlichen und fibrotischen prozessen
Idkowiak-Baldys et al. Growth differentiation factor 11 (GDF11) has pronounced effects on skin biology
DE69940980D1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
ATE203766T1 (de) Teil der intronsequenz des von hippel-lindau(vhl)-gens und seine verwendung zur krankheitsdiagnose
NO994750L (no) Anti-Fas-antistoffer
WO1999028461A3 (en) Methods and means for inducing apoptosis by interfering with bip-like proteins
EA200100278A1 (ru) Способы модулирования киназных белков множественных линий и скрининга соединений, которые модулируют киназные белки множественных линий
WO2000018961A3 (en) Expression analysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
DE69628431D1 (de) Verwendungen von apoptin
Vater Ultrastructural and immunocytochemical observations on the superior olivary complex of the mustached bat
Lupo et al. Protease inhibitors‐based therapy induces acquired spherocytic‐like anaemia and ineffective erythropoiesis in chronic hepatitis C virus patients
ATE275200T1 (de) Genabgabe-vehikel die das apoptosis vp2 inducierendes protein, und/oder apoptin exprimiert
EA200401390A1 (ru) N-ацетилглюкозамин-6-фосфатдеацетилаза человека, взаимодействующая с каспазой-8, и способы ее применения
ATE214101T1 (de) Expression von heterologen genen in menschlichen brustzellen, einschliesslich menschliche brustkarzionomzellen unter der kontrolle von regulatorischen sequenzen von wap oder mmtv
ATE323176T1 (de) Nachweis von brusttumorvirus-artigen sequenzen in brustkrebs bei menschen
DE59712847D1 (de) Monoklonaler Antikörper gegen MxA und MxB
Sistler et al. Cultural diversity in coping with marital stress.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees